Program record
Asset identity, stage, indication, owners, milestones, risks, decisions, and handoffs.
Open lifecycle controlFrom specialist evidence to one accountable decision.
Move from discovery through regulatory and lifecycle decisions with methods, uncertainty, ownership, and rationale kept visible in one reviewable record.
Run a Discovery Campaign
Explore the labelled decision record
Choose a development stage
Plan a focused pilot
BayesPharma Copilot INNOVATOR
Target · molecule · candidate · programme · decision
Methods stay inspectable
Uncertainty stays visible
Experts retain authority
Flagship therapeutic discovery workspace
Design small molecules and biologics in one connected environment.
Connect disease biology, human genetics, omics, modality selection, molecular AI, experiments, DMPK, toxicology, PBPK, PopPK, TMDD, CMC and clinical translation—without losing evidence provenance, uncertainty or qualified human review.
Small moleculesAntibodiesNanobodiesProteinsPeptidesRNAVaccines
Living programme workflowConnected
Biology and evidenceDisease mechanism · genetics · omics · target confidence
01Modality strategySmall molecule · antibody · protein · RNA comparison
02Design and computationMolecular AI · structure · docking · sequence design
03Experiment and learningAssays · uncertainty · active learning · model calibration
04Translate and developDMPK · safety · PBPK · PopPK · TMDD · CMC
05Governed decisionEvidence state · reviewers · rationale · next action
06Decision outputAdvance, close gaps, redesign, pause or stop—with provenance, uncertainty and human authority preserved.
One operating model, four connected layers
Keep program context, science, review, and learning connected.
Specialist workspaces remain focused on their methods. BayesPK Innovator connects their outputs to the development question, evidence state, accountable reviewers, and downstream decisions.
Scientific evidence
Versioned data, methods, models, assumptions, diagnostics, limitations, and context of use.
Inspect model evidenceReview and decisions
Named ownership, review posture, dissent, rationale, conditions, and approval boundaries.
Inspect a decision recordOutcome learning
Predictions, observed outcomes, assumption performance, model reuse, and program learning.
Inspect the learning loop
Molecule-to-lifecycle evidence spine
Six decision horizons. One continuously reviewable record.
Each horizon asks a different scientific question. The evidence and rationale continue forward so the development story does not have to be reconstructed at every gate.
- 01Therapeutic hypothesisWhat mechanism, modality and therapeutic design should we test?Therapeutic Design OS
- 02CandidateWhich candidate has a credible path forward?Candidate OS
- 03DevelopabilityCan the molecule become a viable product?Developability
- 04Clinical MIDDWhat dose, design, and population should advance?Clinical Program OS
- 05RegulatoryIs the evidence claim-ready and reviewable?IND/NDA intelligence
- 06LifecycleWhat changed, what held, and what should be reused?Lifecycle OS
Proof inside the product
Inspect a decision record—not another confidence score.
This public tour uses labelled illustrative content to show how Innovator keeps scientific evidence, uncertainty, review, and downstream action attached to a decision.
Active-dose decision · illustrative record
The recommendation is attached to evidence, uncertainty, ownership, and conditions.
Reviewers can see what is being decided, why now, which records support it, what remains uncertain, and who must authorize the next step.
Cross-functional review openDecisionAdvance exposure range for protocol simulation
EvidenceCurrent model and safety records linked
Open conditionReconcile high-exposure safety assumption
AuthorityQualified human reviewers retain approval
One record, role-specific decisions
Start from the outcome your team owns.
Each role sees the same controlled program context through a different decision lens. The evidence does not fork into competing copies.
Role outcome
Control the next consequential program decision.
See stage posture, evidence movement, scientific blockers, named owners, review state, and the next accountable action.
Open Lifecycle OS- Program state with explicit uncertainty
- Cross-functional owners and review posture
- Traceable decision and handoff history
Canonical decision workflows
Open a complete decision path, not an isolated calculation.
These entry points connect specialist analysis to evidence state, accountable review, decision rationale, and the next handoff.
01 · Discovery and therapeutic design
Biology to designed therapeutic
Connect disease biology, modality strategy, molecular or biological design, experiments, developability and translational evidence in one governed workflow.
Open Therapeutic Design OS 02 · Managed discovery campaignTarget to docking-ranked candidates
Run a client-facing campaign from validated target readiness and compute approval through molecule generation, chemistry/diversity, real docking, pose consensus, live progress, and final candidates for human/CRO review.
Run Discovery Campaign 03 · TranslationCandidate to first-in-human
Bring ADME, safety, translational assumptions, exposure expectations, and starting-dose rationale into one shared profile.
Open Candidate OS 04 · CMCDevelopability and product strategy
Review solid form, formulation, biopharmaceutics, manufacturability risk, and the next evidence-generating experiment.
Open Developability 05 · Clinical MIDDDose and trial decision intelligence
Keep PopPK, PBPK, PK/PD, simulation, endpoints, diagnostics, and dose rationale on one evidence spine.
Open Clinical Program OS 06 · RegulatoryClaim-to-source authoring control
Connect claims, sources, artifacts, readiness, reviewers, CTD plans, and controlled submission handoffs.
Open IND/NDA intelligence 07 · AssuranceModel credibility and governed reuse
Make context of use, diagnostics, uncertainty, validation evidence, limitations, and reuse conditions inspectable.
Open Credibility StudioComplete workspace directoryBrowse every Innovator workspace Open directory
Open the directory to load workspaces.
Make the evidence inspectable—and keep qualified humans in control.
BayesPK Innovator supports traceable analysis and accountable review. It does not autonomously approve a development decision, replace scientific judgment, qualify a deployment, or communicate with a regulator.
Context-of-use evidenceRecord intended use, method version, applicability, diagnostics, uncertainty, and limitations.
Named review authorityKeep reviewer identity, posture, rationale, conditions, and dissent attached to the decision.
Traceable change historyPreserve source movement, evidence versions, model changes, handoffs, and superseded rationale.
Prediction-to-outcome learningCompare assumptions and predictions with observed outcomes before reuse or expansion.
Bring one difficult development decision.
Tell us the program stage, fragmented evidence, and outcome that matters. We will shape the walkthrough around one credible decision path instead of a broad module tour.